56 Results for "

ERK1/ERK2

" in MedChemExpress (MCE) Product Catalog:
Products (56)

56 Results for "ERK1/ERK2" in MCE Product Catalog:

  • Targets Recommended:
193
193 Publications Verification
Cat. No.: HY-50846
CAS No.: 942183-80-4
Target:  

ERK

Research Areas:  

Neurological Disease Cancer

SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naive and MAPK inhibitor-resistant cells containing BRAF or RAS mutations [1].
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15816
CAS No.: 869886-67-9
Purity:  99.95%
Synonyms: BVD-523; VRT752271
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line [1] [2].
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15816A
CAS No.: 1956366-10-1
Purity:  99.89%
Synonyms: BVD-523 hydrochloride; VRT752271 hydrochloride
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line [1] [2].
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-15947
CAS No.: 1453848-26-4
Synonyms: GDC-0994
Target:  

ERK

Research Areas:  

Cancer

Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-15947A
CAS No.: 2070009-58-2
Synonyms: GDC-0994 hydrochloride
Target:  

ERK

Research Areas:  

Cancer

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-101494
CAS No.: 1951483-29-6
Purity:  99.94%
Synonyms: LY3214996
Target:  

ERK

Research Areas:  

Cancer

Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-12275
CAS No.: 865362-74-9
Purity:  99.91%
Research Areas:  

Cancer

FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively [1].
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-112287
CAS No.: 2095719-90-5
Purity:  99.58%
Target:  

ERK

Research Areas:  

Cancer

ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively [1].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0590
CAS No.: 630-94-4
Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent ERK1/ERK2 inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-W010907
CAS No.: 6640-22-8
Target:  

GPR35 ERK

Research Areas:  

Neurological Disease

Pamoic acid disodium is a potent GPR35 agonist with an EC50 value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect [1].
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P80393
Synonyms: MAP kinase 3; MAPK 3; ERK-1; p44-MAPK; MAP kinase 1; MAPK 1; ERK-2; p42-MAPK

Host:  

Rabbit

Application:  

WB, ICC/IF, IP, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108330
CAS No.: 118409-62-4
Purity:  ≥98.0%
Synonyms: Tyrphostin AG126
Target:  

ERK Mitosis

Research Areas:  

Inflammation/Immunology

AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of ERK1 and ERK2 at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research [1] [2] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N1374
CAS No.: 31008-18-1
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC50s of 87 nM and 16.5 nM, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1342
CAS No.: 196391-82-9
Research Areas:  

Neurological Disease

Prosaptide Tx14(A), a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC50s of 5 and 7 nM, respectively. Prosaptide Tx14(A) increases both ERK1 and ERK2 phosphorylation in Schwann cells [1] [2].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-14604
CAS No.: 90494-79-4
Purity:  98.57%
Synonyms: SR57746A; SR57746 hydrochloride
Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety [1] [2] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1342A
Target:  

ERK

Research Areas:  

Neurological Disease

Prosaptide Tx14(A) TFA, a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC50s of 5 and 7 nM, respectively. Prosaptide Tx14(A) TFA increases both ERK1 and ERK2 phosphorylation in Schwann cells [1] [2].
loading...
    loading...
Cat. No.: HY-114491
CAS No.: 1715025-32-3
Purity:  99.83%
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF [1] [2].
loading...
    loading...
Cat. No.: HY-143212
CAS No.: 65886-80-8
Synonyms: 1-Stearoyl-2-docosahexaenoyl-sn-glycerol
18:0-22:6 DG (1-Stearoyl-2-docosahexaenoyl-sn-glycerol) is a diacylglycerol (DG) that can interact with RasGRP (Ras guanine nucleotide-releasing protein) (Ki = 8.37 μM) and modulate the activation of MAP kinases (such as ERK1/ERK2), which play a crucial role in cellular signaling processes. 18:0-22:6 DG can also activate protein kinase C (PKC) isozyme. 18:0-22:6 DG can be used for research of cancer, immunology and metabolic disease [1] [2].
loading...
    loading...
Cat. No.: HY-150700
CAS No.: 2784577-71-3
Purity:  99.79%
Target:  

ERK

Research Areas:  

Metabolic Disease

RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome [1].
loading...
    loading...
Cat. No.: HY-151367
CAS No.: 2494010-42-1
Purity:  98.63%
Target:  

ERK

Research Areas:  

Cancer

SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC50 values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC50 value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer [1].
loading...
    loading...